Raymond James Financial
TELO icon

Raymond James Financial’s Telomir Pharmaceuticals TELO Stock Holding History

Raymond James Financial’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-75,340
Closed -$105K – 5348
2025
Q3 		$105K Buy
75,340
+73,547
+4,102% +$111K ﹤0.01% 4742
2025
Q2 		$2.24K Buy
+1,793
New +$4.14K ﹤0.01% 6385

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Raymond James Financial's TELO Position: Q4 2025 in Review

Raymond James Financial sold out of Telomir Pharmaceuticals (TELO) in Q4 2025, closing a stake of 75,340 shares — an estimated $105K sold.

Raymond James Financial first reported a position in TELO in Q2 2025 and held it in 2 quarters. The position peaked at $105K in Q3 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q4 2025.

  • Raymond James Financial reported no remaining Telomir Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Raymond James Financial sold 75,340 Telomir Pharmaceuticals shares in Q4 2025, an estimated $105K.
  • Raymond James Financial first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Telomir Pharmaceuticals position peaked at $105K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q4 2025.

Based on Raymond James Financial's 13F filing for Q4 2025, filed 18 Feb 2026.